Chapin Davis Inc. Purchases New Stake in DaVita Inc. $DVA

Chapin Davis Inc. purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 4,548 shares of the company’s stock, valued at approximately $1,012,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Root Financial Partners LLC boosted its stake in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares in the last quarter. Caitlin John LLC acquired a new stake in DaVita in the fourth quarter valued at $34,000. Canada Pension Plan Investment Board acquired a new stake in DaVita in the 2nd quarter valued at about $43,000. Sankala Group LLC acquired a new position in DaVita during the fourth quarter worth about $39,000. Finally, iSAM Funds UK Ltd purchased a new stake in shares of DaVita in the third quarter valued at about $46,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.90% of the stock is owned by corporate insiders.

DaVita Stock Performance

DVA opened at $188.59 on Thursday. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49. The firm has a 50 day moving average price of $218.97 and a 200 day moving average price of $175.94. The company has a market cap of $12.11 billion, a PE ratio of 15.43, a price-to-earnings-growth ratio of 0.75 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 231.38%. The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the prior year, the company earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts predict that DaVita Inc. will post 15.07 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a research report on Monday, June 8th. Barclays boosted their target price on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. UBS Group upped their price objective on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Truist Financial lifted their target price on shares of DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Two equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $225.00.

DaVita News Roundup

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported adjusted EPS of $4.02, above the roughly $3.88–$4.01 consensus range, while revenue reached $3.554 billion versus expectations near $3.50 billion. EPS increased from $2.95 a year earlier, and revenue grew 5.2% year over year. DaVita Inc. 2nd Quarter 2026 Results
• Positive Sentiment: Management highlighted clinical-led treatment-volume growth, mortality-related volume gains and broader access to “middle molecule” therapies. Adjusted operating income was $579 million and free cash flow was $256 million, supporting continued investment and share repurchases. DVA Q2 Earnings Call Centers on Clinical-Led Volume Growth
• Positive Sentiment: Barclays raised its price target from $218 to $224, implying meaningful potential recovery from recent trading levels, although it retained an “equal weight” rating. Barclays price target report
• Neutral Sentiment: Options activity was unusually high, with traders buying 9,484 call contracts—564% above average. This may reflect bullish positioning or hedging, but it does not establish a clear direction for the stock.
• Negative Sentiment: U.S. dialysis revenue per treatment fell to $415.87 from $417.59 in the prior quarter because of payer-mix changes and normal fluctuations. A weaker commercial mix and reimbursement pressure are raising concerns about profitability. DaVita Stock Down Despite Q2 Earnings Beat
• Negative Sentiment: DaVita reaffirmed, rather than raised, its FY 2026 adjusted EPS outlook of $14.10–$15.20, adjusted operating income guidance of $2.15–$2.25 billion and free-cash-flow forecast of $1.0–$1.25 billion. Investors may have expected an upward revision after the first-quarter increase.
• Negative Sentiment: Higher general and administrative expense, which rose to $331 million from $320 million sequentially, and concerns about narrowing margins further weakened the market’s reaction to otherwise solid results.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.